Literature DB >> 15271942

Murine model of pulmonary anthrax: kinetics of dissemination, histopathology, and mouse strain susceptibility.

C Rick Lyons1, Julie Lovchik, Julie Hutt, Mary F Lipscomb, Eugenia Wang, Sara Heninger, Lucy Berliba, Kristin Garrison.   

Abstract

Bioweapons are most often designed for delivery to the lung, although this route is not the usual portal of entry for many of the pathogens in the natural environment. Vaccines and therapeutics that are efficacious for natural routes of infection may not be effective against the pulmonary route. Pulmonary models are needed to investigate the importance of specific bacterial genes in virulence, to identify components of the host immune system that are important in providing innate and acquired protection, and for testing diagnostic and therapeutic strategies. This report describes the characteristics of host and Bacillus anthracis interactions in a murine pulmonary-infection model. The infective dose varied depending on the route and method of inoculation. The germination process in the lung began within 1 h of inoculation into the lung, although growth within the lung was limited. B. anthracis was found in the lung-associated lymph nodes approximately 5 h after infection. Minimal pneumonitis was associated with the lung infection, but significant systemic pathology was noted after dissemination. Infected mice typically succumbed to infection approximately 3 to 4 days after inoculation. The 50% lethal doses differed among inbred strains of mice, but within a given mouse strain, neither the age nor the sex of the mice influenced susceptibility to B. anthracis.

Entities:  

Mesh:

Year:  2004        PMID: 15271942      PMCID: PMC470666          DOI: 10.1128/IAI.72.8.4801-4809.2004

Source DB:  PubMed          Journal:  Infect Immun        ISSN: 0019-9567            Impact factor:   3.441


  38 in total

Review 1.  Anthrax toxin.

Authors:  R Bhatnagar; S Batra
Journal:  Crit Rev Microbiol       Date:  2001       Impact factor: 7.624

2.  The Sverdlovsk anthrax outbreak of 1979.

Authors:  M Meselson; J Guillemin; M Hugh-Jones; A Langmuir; I Popova; A Shelokov; O Yampolskaya
Journal:  Science       Date:  1994-11-18       Impact factor: 47.728

3.  Anthrax spores make an essential contribution to vaccine efficacy.

Authors:  Fabien Brossier; Martine Levy; Michèle Mock
Journal:  Infect Immun       Date:  2002-02       Impact factor: 3.441

4.  Germination of Bacillus anthracis spores within alveolar macrophages.

Authors:  C Guidi-Rontani; M Weber-Levy; E Labruyère; M Mock
Journal:  Mol Microbiol       Date:  1999-01       Impact factor: 3.501

5.  Germination of Bacillus cereus spores in response to L-alanine and to inosine: the roles of gerL and gerQ operons.

Authors:  Paul J Barlass; Christopher W Houston; Mark O Clements; Anne Moir
Journal:  Microbiology       Date:  2002-07       Impact factor: 2.777

6.  Pathology of inhalational anthrax in 42 cases from the Sverdlovsk outbreak of 1979.

Authors:  F A Abramova; L M Grinberg; O V Yampolskaya; D H Walker
Journal:  Proc Natl Acad Sci U S A       Date:  1993-03-15       Impact factor: 11.205

7.  Bacillus anthracis lethal toxin induces TNF-alpha-independent hypoxia-mediated toxicity in mice.

Authors:  Mahtab Moayeri; Diana Haines; Howard A Young; Stephen H Leppla
Journal:  J Clin Invest       Date:  2003-09       Impact factor: 14.808

8.  Bacillus anthracis protective antigen, expressed in Salmonella typhimurium SL 3261, affords protection against anthrax spore challenge.

Authors:  N M Coulson; M Fulop; R W Titball
Journal:  Vaccine       Date:  1994-11       Impact factor: 3.641

9.  Inhalational Anthrax.

Authors:  Erwin Kurt Cullamar; Larry I. Lutwick
Journal:  Curr Infect Dis Rep       Date:  2002-06       Impact factor: 3.663

10.  Epidemiologic investigations of bioterrorism-related anthrax, New Jersey, 2001.

Authors:  Carolyn M Greene; Jennita Reefhuis; Christina Tan; Anthony E Fiore; Susan Goldstein; Michael J Beach; Stephen C Redd; David Valiante; Gregory Burr; James Buehler; Robert W Pinner; Eddy Bresnitz; Beth P Bell
Journal:  Emerg Infect Dis       Date:  2002-10       Impact factor: 6.883

View more
  68 in total

1.  Pre- and postexposure protection against virulent anthrax infection in mice by humanized monoclonal antibodies to Bacillus anthracis capsule.

Authors:  Zhaochun Chen; Rachel Schneerson; Julie Lovchik; C Rick Lyons; Huaying Zhao; Zhongdong Dai; Joanna Kubler-Kielb; Stephen H Leppla; Robert H Purcell
Journal:  Proc Natl Acad Sci U S A       Date:  2010-12-27       Impact factor: 11.205

2.  Morphogenesis of the Bacillus anthracis spore.

Authors:  Rebecca Giorno; Joel Bozue; Christopher Cote; Theresa Wenzel; Krishna-Sulayman Moody; Michael Mallozzi; Matthew Ryan; Rong Wang; Ryszard Zielke; Janine R Maddock; Arthur Friedlander; Susan Welkos; Adam Driks
Journal:  J Bacteriol       Date:  2006-11-17       Impact factor: 3.490

3.  Fully virulent Bacillus anthracis does not require the immunodominant protein BclA for pathogenesis.

Authors:  J Bozue; C K Cote; K L Moody; S L Welkos
Journal:  Infect Immun       Date:  2006-10-30       Impact factor: 3.441

4.  Capsule synthesis by Bacillus anthracis is required for dissemination in murine inhalation anthrax.

Authors:  Melissa Drysdale; Sara Heninger; Julie Hutt; Yahua Chen; C Rick Lyons; Theresa M Koehler
Journal:  EMBO J       Date:  2004-12-16       Impact factor: 11.598

5.  Histopathology in a murine model of anthrax.

Authors:  Scott Duong; Lucius Chiaraviglio; James E Kirby
Journal:  Int J Exp Pathol       Date:  2006-04       Impact factor: 1.925

6.  Bacillus anthracis phospholipases C facilitate macrophage-associated growth and contribute to virulence in a murine model of inhalation anthrax.

Authors:  Brian J Heffernan; Brendan Thomason; Amy Herring-Palmer; Lee Shaughnessy; Rod McDonald; Nathan Fisher; Gary B Huffnagle; Philip Hanna
Journal:  Infect Immun       Date:  2006-07       Impact factor: 3.441

7.  The Bacillus anthracis protein MprF is required for synthesis of lysylphosphatidylglycerols and for resistance to cationic antimicrobial peptides.

Authors:  Shalaka Samant; Fong-Fu Hsu; Alexander A Neyfakh; Hyunwoo Lee
Journal:  J Bacteriol       Date:  2008-12-12       Impact factor: 3.490

8.  Bacillus anthracis has two independent bottlenecks that are dependent on the portal of entry in an intranasal model of inhalational infection.

Authors:  David E Lowe; Stephen M C Ernst; Christine Zito; Jason Ya; Ian J Glomski
Journal:  Infect Immun       Date:  2013-09-16       Impact factor: 3.441

9.  Transcriptional profiling of Bacillus anthracis during infection of host macrophages.

Authors:  Nicholas H Bergman; Erica C Anderson; Ellen E Swenson; Brian K Janes; Nathan Fisher; Matthew M Niemeyer; Amy D Miyoshi; Philip C Hanna
Journal:  Infect Immun       Date:  2007-04-30       Impact factor: 3.441

10.  Discriminating virulence mechanisms among Bacillus anthracis strains by using a murine subcutaneous infection model.

Authors:  Hitendra S Chand; Melissa Drysdale; Julie Lovchik; Theresa M Koehler; Mary F Lipscomb; C Rick Lyons
Journal:  Infect Immun       Date:  2008-11-03       Impact factor: 3.441

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.